Figure 1
From: A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
(a) Immunoblots of proteins from three mantle cell MCL cell lines demonstrating constitutive activation of mTOR and the downstream proteins S6RP and 4EBP1. (b) Everolimus is a potent inhibitor of p-S6RP in both MCL (Jeko) and diffuse large B-cell lymphoma (DHL6) cell lines. Everolimus has less effect on p-4EBP1 in Jeko and no effect on DHL6.
